Medication-Based Treatment (MBT)
Medication Based Treatment (MAT) of substance use disorders involves a combination of a medications that targets the brain, and psychosocial interventions (e.g., counseling, skills development) aimed at improving treatment outcomes. Research shows that medications and therapy together may be more successful than either treatment method alone. Read more from PCSS.
Nurse Practitioners and Physician Assistants:
Nurse Practitioners (NP) and Physician Assistants (PA) are required to complete 24 hours of training including the 8 hour MBT training to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. More info from SAMHSA
Physicians require 8 hours of training to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. More info from SAMHSA
In Person Training
For Physicians, Nurse Practitioners, and Physician’s Assistants.
Apply for Waiver:
To receive a waiver to practice opioid dependency treatment with approved buprenorphine medications, a provider must notify the SAMHSA Center for Substance Abuse Treatment (CSAT) of their intent to practice this form of medication-assisted treatment (MAT). The notification of intent must be submitted to CSAT after completing the required MAT training and before the initial dispensing or prescribing of opioid treatment.
SAMHSA's Waiver Application
Prescription Drug Monitoring Program (PDMP):
The PDMP monitors dispensed drugs that contain controlled dangerous substances (CDS). The goal of the PDMP is to assist medical, pharmacy, and public health professionals in the identification and prevention of prescription drug abuse. It also promotes a balanced use of prescription data that preserves the professional practice of healthcare providers and legitimate access to optimal pharmaceutical care.